GeriMedRisk Geriatric Clinical Pharmacology Rounds

GeriMedRisk offers free monthly webcast accredited educational rounds on topics related to safe prescribing for older adults. For more information please join our mailing list. Registration is required to attend.


Upcoming GeriMedRisk Virtual Rounds: 



GeriMedRisk September Rounds

Sept. 14, 2021  | 12-1 PM EST

Natural Health Products Used for Cognition and their Drug Interactions


Missed Sept. 14th Rounds?

We will be hosting an additional webinar session that will broadcast a recording of Dr. Joanne Ho's presentation


Replay session: Sept. 22 at 7 pm EST

Please note: this session will not be interactive

Click Here to register for the recorded session





Dr. Joanne Ho, MD, FRCPC, MSc

Dr. Joanne Ho is a geriatrician, clinical pharmacologist and internist from the Kitchener Waterloo area and Associate Professor with the Department of Medicine, Divisions of Geriatric Medicine and Clinical Pharmacology and Toxicology, McMaster University. She is the co-founder of GeriMedRisk, and also serves as Co-Executive Director and consultant geriatrician and clinical pharmacologist.


Learning Objectives:

  1. Summarize pharmacology, evidence for benefit and harm for the top 3-5 supplements
  2. Identify clinical relevant interactions

Post Rounds:

Complete your anonymous presenter evaluation here
All registered attendees will receive an attendance certificate.



GeriMedRisk October Rounds
Oct. 5, 2021  | 12-1 PM EST

Digoxin in Older Adults


Click Here to Register for GeriMedRisk October Rounds





Dr. Victoria Chuen, MD PGY3

Dr. Victoria Chuen is a PGY3 in Internal Medicine at McMaster University, Waterloo Regional Campus. She has interests in delirium, medical education and is currently exploring the perspectives of geriatric specialists on using virtual care with older adults. She is hoping to pursue further subspecialty training in Geriatric Medicine next year.


Learning Objectives:

  1. Review the history of digoxin and its mechanism of action.
  2. Understand the pharmacokinetics of digoxin and relevant age-related changes affecting digoxin dosing and monitoring
  3. Review drug-drug interactions involving digoxin and other commonly used medications



Post rounds:

Complete your anonymous presenter evaluation here
All registered attendees will receive an attendance certificate.

Please note: we will not be hosting a replay event or sharing slides from this session.



GeriMedRisk November Rounds

Nov. 2, 2021  | 12-1 PM EST
Clinical Pearls in Osteoporosis


Click Here to Register for GeriMedRisk November Rounds





Dr. Rick Adachi   BSc, MD, FRCP(C)   

Dr. Rick Adachi is a Professor of Medicine at the Michael G. DeGroote School of Medicine,

McMaster University. He is the Actavis Chair for Better Bone Health in Rheumatology.  Dr. Adachi has been involved in clinical trials and epidemiologic research. He either holds or is a co-investigator in several CIHR funded studies including the 20 year Canadian Multicentre Osteoporosis Study (CaMOS), and a separate study examining pQCT, HRpQCT and pMRI images of bone structure and strength to determine the relationship of bone structure and

muscle to fractures in a subset of CaMOS subjects.

Dr Adachi has over 590 peer reviewed publications and is a respected leader in bone research in Canada and Internationally. He was awarded the Lindy Fraser Award by Osteoporosis Canada. In 2006, he received the North American Menopause Society award for Innovation in Osteoporosis Research. In 2012, he received the Queen Elizabeth II Diamond Jubilee Medal for his work in osteoporosis and in 2014 he was received the Olof Johnell Science Award that honours an individual who has contributed to the field of osteoporosis in a scientific or policy implementation area worldwide. In 2019 he was awarded the Herbert Fleisch Medal by ESCEO-IOF in recognition of his outstanding and innovative contributions in basic or translational science.


Learning Objectives:

This presentation will address the following topic areas:

  1. How do we assess fracture risk? What do we mean by imminent fracture risk?
  2. What are the benefits and risks of osteoporosis treatment?
  3. Drug holidays: When do we stop therapy, if ever?
  4. What do RCT’s of bisphosphonate versus denosumab tell us?
  5. When do you measure BMD? Does change in BMD reflect fracture risk reduction?
  6. What is Romosozumab?


Post rounds:

Complete your anonymous presenter evaluation here
All registered attendees will receive an attendance certificate.


At GeriMedRisk we believe in ensuring that our education and resources are current, scientifically based and reflective of best practices. Due to the risk of material from our rounds presentations being altered or incorrectly interpreted, we are unable to attach or forward the presentation slide deck. 


GeriMedRisk- Geriatric Clinical Pharmacology Rounds is a self-approved group learning activity (Section 1) as defined by the Maintenance of Certification program of The Royal College of Physicians and Surgeons of Canada.